Bank Julius Baer & Co
FULC icon

Bank Julius Baer & Co’s Fulcrum Therapeutics FULC Stock Holding History

Bank Julius Baer & Co’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,500
Closed -$24K – 572
2023
Q1 		$24K Hold
8,500
– – ﹤0.01% 543
2022
Q4 		$62K Buy
8,500
+134
+2% +$874 ﹤0.01% 504
2022
Q3 		$68K Sell
8,366
-134
-2% -$959 ﹤0.01% 488
2022
Q2 		$42K Hold
8,500
– – ﹤0.01% 534
2022
Q1 		$201K Hold
8,500
– – ﹤0.01% 413
2021
Q4 		$150K Hold
8,500
– – ﹤0.01% 572
2021
Q3 		$240K Buy
8,500
+8
+0.1% +$152 ﹤0.01% 525
2021
Q2 		$89K Buy
+8,492
New +$85.9K ﹤0.01% 643

Other funds holding FULC

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank Julius Baer & Co's FULC Position: Q2 2023 in Review

Bank Julius Baer & Co sold out of Fulcrum Therapeutics (FULC) in Q2 2023, closing a stake of 8,500 shares — an estimated $24K sold.

Bank Julius Baer & Co first reported a position in FULC in Q2 2021 and held it in 8 quarters. The position peaked at $240K in Q3 2021. 88 funds tracked by Wall St. Rank hold FULC as of Q2 2023.

  • Bank Julius Baer & Co reported no remaining Fulcrum Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Bank Julius Baer & Co sold 8,500 Fulcrum Therapeutics shares in Q2 2023, an estimated $24K.
  • Bank Julius Baer & Co first reported a position in Fulcrum Therapeutics in Q2 2021 and held it in 8 quarters.
  • Bank Julius Baer & Co's Fulcrum Therapeutics position peaked at $240K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2023.

Based on Bank Julius Baer & Co's 13F filing for Q2 2023, filed 20 Jul 2023.